Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5217790 in high-grade cervical intraepithelial neoplasia 2/3 associated with high-risk HPV
2008-006946-24Phase 2Terminated
- Sponsor
- Roche
- Start
- May 2009
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN), human papillomavirus infection and HPV16 infection (HPV16) comparing RO5217790 arm with Placebo arm (2 arms). Primary endpoints: Histological response at month 6 in HPV16 single infection and Safety of RO5217790. Started May 2009; status: terminated.
02
Drugs
tipapkinogene sovacivec
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infectionHPV16 infection (HPV16)
Beyond the preview
Go deeper on 2008-006946-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006946-24.